Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YY-20394 in Relapsed or Refractory Peripheral T-Cell Lymphoma
NCT04108325Phase 1Unknown
- Sponsor
- Yingli Pharma
- Start
- Mar 2020
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of linperlisib in peripheral T-cell lymphoma (PTCL), sponsored by Yingli Pharma. Primary endpoints: Overall Response Rate at 12 months, Disease Control Rate at 12 months and 1 more. Status: unknown.
02
Drugs
linperlisib
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT04108325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04108325.